Nodular malignant melanoma

Summary

Nodular malignant melanoma (MONDO:0000930) is a cancer and 1 clinical trial. A subtype of cutaneous melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nodular malignant melanoma
Mondo ID	MONDO:0000930
EFO	EFO:0008515
DOID	DOID:10047
NCIT	C4225
SNOMED CT	254731001
UMLS	C0334424
MedGen	83144
GARD	0009961
Is cancer (heuristic)	yes

Also known as: nodular cutaneous (skin) melanoma · nodular malignant melanoma of skin · nodular malignant melanoma of the skin · nodular malignant skin melanoma · nodular melanoma (morphologic abnormality)

Disease family

This is a subtype of cutaneous melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › cutaneous melanoma › nodular malignant melanoma

Related subtypes (9): eyelid melanoma, balloon cell malignant melanoma, acral lentiginous melanoma, amelanotic skin melanoma, superficial spreading melanoma, lentigo maligna melanoma, desmoplastic melanoma, spitzoid melanoma, melanoma in congenital melanocytic nevus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01120275	PHASE2	TERMINATED	Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma